Treatment Types and Financial Planning
Patients in Hauppauge exploring ketamine therapy will generally encounter two treatment pathways, each with different financial implications. Off-label treatments, including intravenous (IV), intramuscular (IM), and sublingual ketamine, are not FDA-approved for psychiatric conditions. As a result, these formulations are rarely covered by health insurance, requiring patients to self-pay. Because the costs for multiple sessions can be substantial, it is crucial to obtain a detailed written estimate from the clinic before starting treatment.
Spravato and Insurance Considerations
Alternatively, Spravato (esketamine) is an FDA-approved nasal spray specifically indicated for certain adult depressive disorders, such as treatment-resistant depression. Due to its approved status, Spravato is more frequently covered by commercial insurers. However, coverage varies, and patients typically must navigate a prior authorization process. Individuals should never rely on coverage promises until official authorization is granted by their insurer, and should be aware of potential deductibles or copays. Additionally, patients must budget for travel and lodging costs associated with repeated clinic visits. For those considering off-label options, it is important to read the FDA warning about the potential risks associated with compounded ketamine products.